This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Joint Venture to Manufacture Anti-Viral and Anti-Bacterial Face Masks
PPK Group Limited (ASX Code: PPK) is pleased to announce that it has partnered with Xefco Pty Ltd (Xefco) to form a new joint venture company, Survivon Ltd (Survivon). Survivon will commence immediate local production of anti-viral, antibacterial face masks using Xefco’s developed technology. An independent study by the Peter Doherty Institute for Infection and Immunity has shown that the technology to be used by Survivon is able to inactivate SARSCoV-2 (the virus associated with COVID-19) in as little as five minutes. Further details on this independent study cited by Xefco are set out in Annexure 1 to this announcement. Survivon will also look to licence this technology to international manufacturers around the world. PPK and Xefco will each own 47.6% of Survivon with the balance held by a senior manager (Matthew Bailey, discussed below).